R-LiNK Project Wrap-up: Enhancing Lithium Treatment for Bipolar Disorder

Published on 24/06/2024
R-LiNK Project Wrap-up Enhancing Lithium Treatment for Bipolar Disorder

The R-LiNK project wraps-up at the end of this month. This initiative, titled "Optimizing Response to Lithium Treatment through Personalized Evaluation of Individuals with Bipolar Disorder Type I (BDI)," focuses on improving lithium treatment outcomes for BDI patients.

Bipolar disorder (BD) is a highly prevalent mental disorder and a leading cause of suicide. Lithium is the primary pharmacological treatment for the prevention of new bipolar disorder episodes or relapses. The objective of this study is to identify the eligibility criteria for treatment with Lithium in BDI in terms of response, safety and tolerability.

The R-LiNK project is funded by the Horizon 2020 program and coordinated by INSERM (France), together with AP-HP (France) as sponsor . Through the course of the study, 169 patients were recruited at 16 sites across 8 different countries. In this study ECRIN supported the regulatory and monitoring activities in the European countries.

R-LiNK website